Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-72 (Cancelled)

73. (Currently Amended) A method of treating a neurological disorder in an animal, comprising:

administering to the animal an effective amount of a compound to stimulate growth of damaged peripheral nerves or to promote neuronal regeneration, where the compound has the formula (I):

$$\begin{array}{c}
Y-(Z)_{n} \\
X \\
N \\
A
\end{array}$$
(I)

where

X, Y, and Z are independently selected from the group consisting of C, O, S, or N, provided that X, Y, and Z are not all C;

$$n$$
 is 1;

$$O$$
 R_1

R₁ is selected from the group consisting of hydrogen, C₁-C₉ straight or branched chain alkyl, C₂-C₉ straight or branched chain alkenyl, aryl, heteroaryl, carbocycle, and heterocycle;

D is selected from the group consisting of a bond, C₁-C₁₀ straight or branched chain alkylene, ethylene (-CH=CH-), and butylene;

 R_2 is a carboxylic acid or a carboxylic acid isostere selected from the group consisting of:

wherein said alkyl, alkenyl, alkylene, ethylene, butylene, aryl, heteroaryl, carbocycle, heterocycle, or R_2 carboxylic acid isostere is optionally substituted with one or more substituents selected from R_3 , where

R₃ is selected from the group consisting of hydrogen, hydroxy, halo, haloalkyl, thiocarbonyl, alkoxy, alkenoxy, alkylaryloxy, aryloxy, arylalkyloxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, alkylthio, sulfonyl, C₁-C₆ straight or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl or alkynyl, aryl, heteroaryl, carbocycle, heterocycle, and CO₂R₄ where R₄ is selected from the group consisting of hydrogen, C₁-C₉ straight or branched chain alkyl, and C₂-C₉ straight or branched chain alkenyl;

or a pharmaceutically acceptable salt, or solvate thereof.

- 74. (Original) The method of claim 73, wherein the neurological disorder is selected from the group consisting of peripheral neuropathies caused by physical injury or disease state, physical damage to the brain, physical damage to the spinal cord, stroke associated with brain damage, and neurological disorders relating to neurodegeneration.
- 75. (Original) The method of claim 73, wherein the neurological disorder is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, and amyotrophic lateral sclerosis.
- 76. (Original) The method of claim 73, wherein the neurological disorder is Alzheimer's disease.
- 77. (Original) The method of claim 73, wherein the neurological disorder is amyotrophic lateral sclerosis.
- 78. (Original) The method of claim 73, wherein said compound is non-immunosuppressive.
- 79. (Previously Presented) The method of claim 73, wherein Y is O, S, or N; R₁ is C₁-C₉ straight or branched chain alkyl or aryl; and D is a bond or CH₂.
- 80. (Currently Amended) A method of treating a neurological disorder in an animal, comprising:

administering to the animal an effective amount of a compound to stimulate growth of damaged peripheral nerves or to promote neuronal regeneration, wherein the compound has the formula (I):

$$X \xrightarrow{N \longrightarrow D} \mathbb{R}_{2}$$

$$A$$

where

X, Y, and Z are independently selected from the group consisting of C, O, S, or N, provided that X, Y, and Z are not all C;

n is 1;

A is

R₁ is selected from the group consisting of hydrogen, C₁-C₉ straight or branched chain alkyl, C₂-C₉ straight or branched chain alkenyl, aryl, heteroaryl, carbocycle, and heterocycle;

D is selected from the group consisting of a bond, C_1 - C_{10} straight or branched chain alkylene, ethylene (-CH=CH-), and butylene;

 R_2 is a carboxylic acid or carboxylic acid isostere selected from the group consisting of:

-COOH, -SO₃H, -SO₂HNR₃, -PO₂H, -CN, -PO(OH)(OR₃), -C(O)NHOH, -C(O)NHSO₂R₃, and -CONHCN;

wherein said alkyl, alkenyl, alkylene, ethylene, butylene, aryl, heteroaryl, carbocycle, heterocycle, or $\underline{R_2}$ earboxylic acid isostere is optionally substituted with one or more substituents selected from R_3 , where

R₃ is selected from the group consisting of hydrogen, hydroxy, halo, haloalkyl, thiocarbonyl, alkoxy, alkenoxy, alkylaryloxy, aryloxy, arylalkyloxy, cyano, nitro, imino, alkylamino, aminoalkyl, sulfhydryl, thioalkyl, alkylthio, sulfonyl, C₁-C₆ or branched chain alkyl, C₂-C₆ straight or branched chain alkenyl or alkynyl, aryl, heteroaryl, carbocycle, heterocycle, and CO₂R₄ where R₄ is selected from the group consisting of hydrogen, C₁-C₉ straight or branched chain alkyl, and C₂-C₉ straight or branched chain alkenyl; or a pharmaceutically acceptable salt, or solvate thereof.

- 81. (Original) The method of claim 80, wherein the neurological disorder is selected from the group consisting of peripheral neuropathies caused by physical injury or disease state, physical damage to the brain, physical damage to the spinal cord, stroke associated with brain damage, and neurological disorders relating to neurodegeneration.
- 82. (Original) The method of claim 80, wherein the neurological disorder is selected from the group consisting of Alzheimer's Disease, Parkinson's Disease, and amyotrophic lateral sclerosis.
- 83. (Original) The method of claim 80, wherein the neurological disorder is Alzheimer's Disease.
- 84. (Original) The method of claim 80, wherein the neurological disorder is amyotrophic lateral sclerosis.

- 85. (Original) The method of claim 80, wherein said compound is non-immunosuppressive.
- 86. (Previously Presented) The method of claim 80, wherein the compound is selected from the group consisting of: